Get started
Author

Lucille A. Ferrante

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A - and NPM1 -altered leukemias
2024 · Min Chul Kwon, Jan Willem Thuring, et al. · Blood · 76
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
2019 · Jacob D Soumerai, Ai Ni, et al. · The Lancet Haematology · 68
A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations
2023 · Elias Jabbour, Emma Searle, et al. · Blood · 52
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
2024 · Emma Searle, Christian Recher, et al. · Blood · 42
First‐in‐human study of JNJ ‐63709178, a CD123 / CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia
2022 · Michael Boyiadzis, Pinkal Desai, et al. · Clinical and Translational Science · 34
PDF
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
2024 · Christian Recher, Jenny O'Nions, et al. · Blood · 27
PDF
Synthesis of mesocyclic and macrocyclic polythioethers using the cesium dithiolate technique
1990 · William N. Setzer, Shahrara Afshar, et al. · Heteroatom Chemistry · 21
Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia
2022 · Min Chul Kwon, Olivier Querolle, et al. · Blood · 16
Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations
2025 · Hartmut Döhner, Andre Schuh, et al. · Blood · 14
PDF
Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations
2025 · Jenny O'Nions, Andrew Wei, et al. · Blood · 5
AML-418: Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax+Azacitidine (VEN+AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations
2025 · Andrew H. Wei, Jordi Esteve Reyner, et al. · Clinical Lymphoma Myeloma & Leukemia · 4
Preclinical Efficacy of the Menin-KMT2A Inhibitor JNJ-75276617 in Combination with Venetoclax and Azacitidine in AML
2023 · Min Chul Kwon, Tinne Verhulst, et al. · Blood · 4
Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)
2025 · Marc Raaijmakers, Hartmut Döhner, et al. · Blood · 3
Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLLTM Real-World Registry
2018 · Anthony R. Mato, Jacqueline C. Barrientos, et al. · Blood · 3
Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma
2014 · Peter Martin, Andre Goy, et al. · Blood · 3
Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations
2026 · Hartmut Döhner, Andre C. Schuh, et al. · Transplantation and Cellular Therapy · 1
Pf383 Prognostic Testing and Treatment Approaches Based on Real‐world Clinical Experience From an Interim Analysis of the Informcll Registry of Patients With Chronic Lymphocytic Leukemia
2019 · A.R. Mato, J.C. Barrientos, et al. · HemaSphere · 1
To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
2019 · Peter Martin, Andre Goy, et al. · Journal of Oncology Pharmacy Practice · 1
Bleximenib in Combination With Intensive Chemotherapy: a Phase 1b Study in Newly Diagnosed Acute Myeloid Leukemia With Kmt2a or Npm1 Alterations
2026 · Hartmut DÖHNER, Andre C SCHUH, et al. · Hematology Transfusion and Cell Therapy
Rp2d Determination of Bleximenib in Combination With Ven+aza: Phase 1b Study in Nd & R/r Aml With Kmt2a Type: Oral Presentation Andrew H. Wei Kmt2a/npm1 Npm1alterations
2026 · Andrew WEIL, Jordi ESTEVE REYNER, et al. · Hematology Transfusion and Cell Therapy
Camelot-2: A phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A rearrangements or NPM1 mutations, Who Are Ineligible for Intensive Chemotherapy
2026 · Elias Jabbour, David A. Sallman, et al. · Transplantation and Cellular Therapy
Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy Followed By Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind phase 3 Study (HOVON 181 AML / AMLSG 37-25)
2026 · Marc Raaijmakers, Hartmut Döhner, et al. · Transplantation and Cellular Therapy
POSTER: AML-388 Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations
2025 · Elias Jabbour, Christian Recher, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-388: Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations
2025 · Elias Jabbour, Christian Recher, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-412 Bleximenib Dose Optimization and Determination of the Recommended Phase 2 Dose (RP2D) From a Phase 1 Study in Patients With Relapsed/Refractory Acute Leukemia (AL) With KMT2A and NPM1 Alterations
2025 · Hagop M. Kantarjian, Emma Searle, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 28
Citation count: 373
H-index: 9
I10-index: 9
Year
Topic
Type